• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virol J . Cyclosporin A alleviates influenza A (H1N1) virus-induced chronic pulmonary inflammation through decreasing IFN-γ-producing T lymphocytes

tetano

Editor, Senior Moderator
Virol J


. 2025 Jul 25;22(1):255.
doi: 10.1186/s12985-025-02887-4. Cyclosporin A alleviates influenza A (H1N1) virus-induced chronic pulmonary inflammation through decreasing IFN-γ-producing T lymphocytes

Wenbin Ding[SUP] #[/SUP][SUP] 1 2 [/SUP], Xin Zhao[SUP] #[/SUP][SUP] 3 [/SUP], Zhengyang Lin[SUP] #[/SUP][SUP] 1 [/SUP], Mengxi Luo[SUP] 1 [/SUP], Nanshan Zhong[SUP] 1 [/SUP], Kefang Lai[SUP] 4 5 [/SUP], Zheng Deng[SUP] 6 7 [/SUP]



Affiliations
Free article Abstract

Influenza causes 3-5 million severe cases globally each year, with severe viral pneumonia often requiring hospitalization for over four weeks. While the inflammatory response to influenza infection helps control viral replication, excessive inflammation is a key driver of disease severity and mortality. Excessive pulmonary lymphocytes, particularly IFN-γ-producing T lymphocytes, contribute significantly to pulmonary inflammation at the late-stage of H1N1 viral infection. Cyclosporin A, a potent T-cell inhibitor, mitigates influenza A virus-induced pulmonary inflammation in mice. However, the therapeutic role of lymphocyte suppression in cyclosporin A-mediated attenuation of H1N1 virus-induced chronic pulmonary inflammation remains unclear. Here, we demonstrated that the viral titer was 0 in all the homogenized lung tissues of mice on Day-21 post a sublethal H1N1 viral infection. H1N1 viral infection caused worsened general condition and pulmonary inflammation with the infiltration of lymphocytes and neutrophils on Day-21 post-infection. The bronchoalveolar lavage fluid of H1N1 virus-infected mice showed a 16-fold higher lymphocyte count compared to neutrophils. H1N1 viral infection significantly elevated both IFN-γ-producing T lymphocyte populations and IFN-γ levels in mouse lungs. H1N1 viral infection additionally expanded IFN-γ-producing T lymphocyte populations in both spleen and peripheral blood. Cyclosporin A treatment significantly mitigated H1N1 viral infection-induced worsened general condition, pulmonary lymphocytic inflammation, increases of pulmonary IFN-γ concentrations and IFN-γ-producing T lymphocytes in the lung, spleen and blood of mice on Day-21 post-infection. Together, lymphocytes may contribute significantly to H1N1 virus-induced chronic pulmonary inflammation. Cyclosporin A may alleviate H1N1 virus-induced chronic pulmonary inflammation through decreasing IFN-γ-producing T lymphocytes.

Keywords: Chronic pulmonary inflammation; Cyclosporin A; Influenza A virus; Interferon-γ; Lymphocytes.

 
Back
Top